Chronic lymphocytic leukemia (CLL) is a malignant, chronic lymphoproliferative disorder characterized by proliferation and accumulation of monoclonal B-cells in the bone marrow, peripheral blood, lymph nodes, liver and spleen.
It is the most common form of adult leukemia in the Western world but rare in Asians.
Exact etiology is unknown but usually associated with genetic aberrations and lesions.
Comprehensive recommendations on coronavirus disease 2019 (COVID-19) for cancer patients have become available following review of guidelines from 63 national/international oncology societies. [Lancet Oncol 2020, doi: 10.1016/S1470-2045(20)30278-3]
The single-agent ibrutinib demonstrates significant and durable survival benefits compared with chlorambucil in the first-line treatment of older patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), including those with high-risk prognostic features, according to 5-year data from the RESONATE-2 study.
A regimen consisting of obinutuzumab plus fludarabine and cyclophosphamide achieves favourable outcomes with manageable toxicity in the treatment of chronic lymphocytic leukaemia (CLL) in physically fit adults, poised as an attractive first-line option in patients who are eligible for potent chemoimmunotherapy, according to data from the phase IIIb GREEN trial.
Ofatumumab proves to be useful in the maintenance treatment of patients with relapsed chronic lymphocytic leukaemia (CLL), according to the final analysis of the phase III PROLONG trial, which has shown that the regimen is well tolerated and substantially extends progression-free survival (PFS).
Acalabrutinib, when combined with obinutuzumab or used as monotherapy, significantly improves progression-free survival (PFS) by 80–90 percent vs chemoimmunotherapy in patients with previously-untreated chronic lymphocytic leukaemia (CLL), results of the phase III ELEVATE TN trial have shown.
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Findings from the updated analysis of the phase III MURANO* trial solidify the role of fixed-dose venetoclax plus rituximab in a majority of patients with relapsed/refractory chronic lymphocytic leukaemia (CLL).
New drug applications approved by US FDA as of 15 - 30 September 2018 which includes New Molecular Entities (NMEs) and new
biologics. It does not include Tentative Approvals. Supplemental approvals may
have occurred since the original approval date.
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.